Core Insights - Teladoc Health (TDOC) is experiencing accelerated growth through its global presence, offering a wide range of virtual healthcare services and solutions across various medical specialties [1][4] - The company operates in over 175 countries, leveraging organic growth, localized clinical networks, and strategic partnerships to deliver customized care solutions [2] - International revenues have shown significant growth, with an 18% increase in 2022 and continued expansion in 2023 and beyond [3][8] Company Performance - Revenues from international operations grew 18% in 2022, with a year-over-year improvement of 19.3% in 2023, 12.3% in 2024, and 9% in the first nine months of 2025 [3][8] - The acquisitions of Best Doctors Advance Medical and MédecinDirect have bolstered the company's international operations [3] - TDOC's shares have decreased by 23.9% year to date, contrasting with the industry's growth of 4.2% [7] Competitive Positioning - The company's international operations provide diversification amid increasing competition in the U.S. market, enhancing its competitive positioning and supporting overseas growth [4][8] - TDOC's broad platform and extensive global network are key factors in realizing operating leverage and improving long-term profitability [4] Valuation and Estimates - TDOC is currently trading at a forward 12-month price-to-sales multiple of 0.48, slightly above the industry average of 0.46 [9] - The Zacks Consensus Estimate for TDOC's fourth-quarter 2025 and first-quarter 2026 loss has narrowed by 1 cent each, while the full-year 2025 estimate has narrowed by three cents [10][11] - The consensus estimates suggest a year-over-year decline in revenues for 2025 but an increase for 2026, with EPS estimates indicating year-over-year increases for both years [11]

Market Overview - Wall Street rebounded after a brief selloff due to renewed U.S.-China trade tensions, with investors optimistic about potential dialogue between the two nations [1][9] - Major indexes displayed resilience, supported by easing monetary policy, solid earnings, and investor confidence in economic stability [2] Investment Strategy - A relative price strength strategy is recommended, focusing on stocks that outperform their sectors despite market turbulence [4][5] - Stocks that have shown better performance than the S&P 500 over the last 1 to 3 months and have solid fundamentals are highlighted as having growth potential [6] Stock Recommendations - **United Natural Foods (UNFI)**: Leading distributor of natural and organic products, with a projected earnings growth of 167.6% for fiscal 2026 and a market cap of $2.5 billion. Shares increased by 102% over the past year [11][12] - **Teladoc Health (TDOC)**: Provides virtual healthcare services, with an expected EPS growth rate of 48.4% over the next 3 to 5 years. The company has a market cap of $6.5 billion and shares have decreased by 6.1% in the past year [13][14] - **Supernus Pharmaceuticals (SUPN)**: Develops treatments for CNS disorders, with a market cap of $2.7 billion and a projected earnings growth of 9.8% for 2025. Shares have risen by 46.8% in the last year [15][16] - **BRP Inc. (DOOO)**: A leader in powersports with a market cap of $4.8 billion, showing a 26.2% increase in earnings estimates for fiscal 2026. Shares gained 19.9% over the past year [17][18] Screening Parameters - Stocks selected based on relative price change over 12 weeks, 4 weeks, and 1 week, alongside positive earnings estimate revisions for the current quarter [8][10]

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and failing to account for rising customer acquisition costs, leading to a significant drop in share value [1][3]. Company Overview - LifeMD, Inc. is a direct-to-consumer telehealth company based in New York, providing virtual healthcare services and pharmacy offerings in areas such as men's health, obesity treatment, and chronic care [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025, with a deadline of October 27, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint claims that LifeMD raised its 2025 guidance recklessly, which contributed to the misrepresentation of its financial health [3]. Financial Impact - Following the revelation of the company's financial issues, LifeMD shares experienced a dramatic decline, losing 44% of their value in a single trading session [3].

Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and LifeMD, Inc. (LFMD) emerging as key players providing direct-to-consumer services [1][2] Company Overview - Hims & Hers is focused on transforming health and wellness needs for consumers, while LifeMD offers cost-effective telehealth solutions for comprehensive virtual and in-home healthcare [2] - HIMS is expanding into Europe through the acquisition of ZAVA, targeting markets such as Germany and France, while LFMD's Wegovy program has enrolled over 75,000 patients, indicating strong market traction [6][8][10] Stock Performance & Valuation - Over the past three months, HIMS has increased by 67.2%, while LFMD has risen by 152.8%. However, in the past year, HIMS has gained 130.7% compared to LFMD's 102.2% [3] - HIMS has a forward price-to-sales (P/S) ratio of 4.3, above its three-year median of 2.3, while LFMD's ratio is 2.2, also above its median of 0.9 [5] Earnings Projections - HIMS expects a 170.4% growth in EPS for 2025, compared to LFMD's projected 107.6% growth [6][15][17] - The Zacks Consensus Estimate for HIMS' 2025 EPS suggests a significant improvement from 2024, while LFMD's estimate also indicates growth [15][17] Strategic Initiatives - HIMS is focusing on expanding into new specialty areas that can be treated via telehealth, such as sleep disorders and hypertension, which align with its business model [7] - LifeMD's Wegovy program integrates medication with virtual care, providing a compliant solution for weight loss therapy, which is in high demand [10][11] Financial Health - LifeMD reported first-quarter revenues of $65.7 million and net income of $1.4 million, showing a turnaround from previous losses, supported by $34.4 million in cash [12] - HIMS is utilizing proceeds from its $870 million convertible senior notes offering to support global expansion and investment in AI and personalized treatments [9] Investment Outlook - HIMS is viewed as a more stable investment opportunity with strong profitability and user engagement, while LFMD is recognized for its rapid growth and expansion [24][25] - Analysts have set average price targets for HIMS at $46.17 and for LFMD at $12.81, both indicating potential declines from their last close [20][22]